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DexmedetomidineAbstract Background: Shivering is a frequent complication following spinal anesthesia (SA). It is
more common in transurethral resection of the prostate (TURP) that may be due to absorption of
large amount of irrigating ﬂuids. We aimed to investigate the role of intrathecal dexmedetomidine
in attenuation and prevention of shivering in patients undergoing TURP under SA.
Methods: In a randomized, controlled trial, eighty patients were scheduled for elective TURP
under SA. Patients were randomly allocated into two groups: control group (group C): patients
received 2.5 ml of hyperbaric bupivacaine 0.5% plus 0.5 ml of normal saline and dexmedetomidine
group (group D); patients received 2.5 ml of hyperbaric bupivacaine 0.5%, plus 10 lg dexmedetom-
idine in 0.5 ml of normal saline. Hemodynamic parameters, shivering score and any adverse effects
were recorded.
Results: The incidence of shivering was signiﬁcantly reduced in group D, 6/40 patients (15%)
compared with 23/40 patients (57%) in group C (P< 0.001). The frequency of bradycardia, hypo-
tension, number of patients treated with meperidine and ephedrine were signiﬁcantly higher in
group D compared with group C (P= 0.048, P= 0.043, P= 0.011, P= 0.043) respectively. There
was insigniﬁcant difference in the incidence of nausea, vomiting and TUR syndrome in patients in
both groups (p> 0.05).
Conclusion: Our results suggest that the use of 10 lg intrathecal dexmedetomidine in patients
undergoing TURP has a noticeable control of shivering even in occurrence of tolerable side effects.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Shivering is a frequent complication following SA [1]. The inci-
dence of shivering has been reported to be about 36–85% after
SA [2]. It is more common in TURP that may be due to
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temperature [3]. Shivering may occur as a response to hypo-
thermia. However, it may also occur in normothermic patients
[4]. SA impairs the thermoregulation system by inhibiting tonic
vasoconstriction below the level of anesthesia through sympa-
thetic and somatic neural blockade [5]. With internal redistri-
bution of heat from the core to the peripheral compartment,
the loss of thermoregulatory vasoconstriction results in
increased heat loss from body surfaces in excess of metabolic
heat production [5]. Shivering causes patient discomfort,
interruption of monitoring, increases O2 consumption, CO2
production, and catecholamine secretion that increase cardiac
output, heart rate, and blood pressure [6].
Many medications have been tried to prevent or reduce
shivering but the ideal one has not been determined yet.
Meperidine was tried alone or in combination with clonidine
and urapidil [7]. Magnesium sulfate [8], ketamine, fentanyl
and morphine have been tried with no convincing results [9].
Dexmedetomidine is highly selective Alpha (a)-2-adrenergic
receptor agonist and is approved to decrease the shivering
threshold. It has sedative, analgesic, sympatholytic, anes-
thetic-sparing and hemodynamic-stabilizing properties. Addi-
tion of intrathecal dexmedetomidine to heavy bupivacaine
0.5% was more advantageous than fentanyl with special
regard to its analgesic properties in diabetic surgical patients
[10,11]. Premedication with IM dexmedetomidine reduces the
incidence of postoperative shivering [12]. Few studies have
been done to evaluate the efﬁcacy of intrathecal dexmedetom-
idine in attenuation and prevention of shivering in TURP [13].
We aimed to investigate the role of intrathecal dexmede-
tomidine in attenuation and prevention of shivering in TURP
under SA in a randomized controlled trial.
2. Patients and methods
After local Ethics Committee approval, written, informed
consent was obtained from all patients participating in this
randomized, double-blinded, controlled trial. Eighty patients,
aged 40–70 years, ASA physical statuses I, II, and III sched-
uled for elective TURP under SA, were enrolled in this study.
Transrectal ultrasound (TRUS) was done for all patients for
detection of prostatic size. Exclusion criteria included: patients
with contraindications to SA, allergy to the study medication,
thyroid disease, Parkinson’s disease and patients receiving
vasodilators or medications likely to alter thermoregulation.
Patients with unstable coronary artery diseases, 2nd and 3rd
degree heart block, congestive heart failure, tight mitral or aor-
tic valve stenosis and ventricular tachyarrhythmia were also
excluded from the study. Past and current medical records
were checked for associated medical disorders and concomi-
tant medication intake. Preoperative serum sodium and hemo-
globin concentration were cheeked. In the pre-anesthesia room
I.V. line was inserted and intravenous preload with isotonic
saline solution was infused to all patients at 10 ml/kg within
30 min. Afterward the rate of isotonic saline solution infusion
was set at 5 ml/kg/h. Patients in both groups were premedicat-
ed with 1–3 mg midazolam intravenously. In the operating
room basic monitoring of ECG, oxygen saturation by pulse
oximetry and noninvasive blood pressure were applied to all
patients and recorded at 5 min intervals using standardmonitors (AS/3; Datex Ohmeda, Bromma, Sweden). Core
body temperature was recorded of all patients on arrival to
the operating room using a tympanic thermometer then at
15 min intervals. Operating room (OR) temperature was main-
tained at 22–24 C. All patients were covered with one layer of
surgical drapes over the chest, thighs, and calves during the
operation. Core temperature below 36 C was considered
hypothermia.
Under aseptic technique, subarachnoid block was per-
formed in sitting position using 25 G spinal needle at either
the L3–L4 or L4–L5 intervertebral spaces. Patients were ran-
domly allocated by the use of sealed envelope assignment into
two groups: control group (group C): patients received 2.5 ml
of hyperbaric bupivacaine 0.5%, plus 0.5 ml of normal saline
and dexmedetomidine group (group D); patients received
2.5 ml of hyperbaric bupivacaine 0.5%, plus 10 lg preservative
free dexmedetomidine (Precedex; Hospira Inc., Lake Forest,
Illinois, USA) in 0.5 ml of normal saline. The study medica-
tions were prepared by an anesthesiologist blinded to the
study. Also SA, data measurements and recording were carried
out by an anesthesiologist blinded to the study. Supplemental
oxygen (5 L/min) was delivered via face mask during surgery
time. After injection of local anesthetic, the assessment of sen-
sory block level was done using pin-prick test (needle prick) to
be above T10 dermatome. Patients with incomplete or failed
SA were subsequently excluded from the study and received
general anesthesia (GA). TURP was performed using a contin-
uous ﬂow resectoscope with monopolar cautery using 1.5%
glycine as an irrigant solution. All intravenous and irrigation
ﬂuids were warmed to 37 C in warming cabinets. Shivering
was assessed by Crossley and Mahajan scale [14] where
0 = No shivering, 1 = Cyanosis and piloerection, 2 = Visible
tremors only in one muscle group, 3 = Visible tremors in more
than one muscle group, and 4 = intense shivering, tremors of
the head, arm. During surgery, shivering score was assessed
and recorded at 15 min intervals. If shivering score was P3,
meperidine 25 mg was administered intravenously. The num-
ber of patients treated for shivering with meperidine was
recorded. Occurrence of signs and symptoms of TUR syn-
drome (blurring of vision, irritability, confusion, convulsion,
etc.) was reported. Any adverse effects such as bradycardia,
hypotension, nausea and vomiting were recorded. Bradycardia
was deﬁned as a decrease in heart rate below 50 beat/min. Bra-
dycardia was treated with IV bolus of atropine 0.5 mg. Hypo-
tension was deﬁned as a decrease in MAP of more than 20%
from baseline. Hypotension was treated with IV boluses of
ephedrine 5–10 mg. The number of patients treated for hypo-
tension with ephedrine was recorded. If patients developed
nausea or vomiting, IV bolus of metoclopramide 10 mg was
administered. Total volume of irrigation solution used for each
patient was recorded by the end of surgery. In the postanesthe-
sia care unit (PACU), ambient temperature was maintained at
25 C to 26 C and all patients were covered with one layer of
drapes and one cotton blanket. Heart rate (HR), mean arterial
blood pressure (MAP), oxygen saturation, core body tempera-
ture and shivering scores were recorded to all patients at
15 min intervals over one hour postoperatively in PACU.
Serum Na and hemoglobin concentration were cheeked once
postoperatively. Anesthesia time, surgery time (resection time)
and any adverse events were also recorded.
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The sample size was calculated using the G Power analysis
program version 3.1. The incidence of shivering related to
SA from previous reports was 55% [15]. The sample size
required to achieve 40% reduction was minimum 33 patients
in each group with a power of 80% and a= 0.05. Eighty
patients were included for the possibility of drop out cases.
Data were analyzed using SPSS (Statistical Package for
Social Sciences) version 15. Qualitative data were presented
as number and percent. Comparison between groups was done
by Chi-Square test. Quantitative data were presented as
mean ± SD. Student t-test was used to compare between
two groups. P< 0.05 was considered to be statistically
signiﬁcant.
4. Results
The two groups were comparable regarding age, BMI, anes-
thesia and surgery times, prostatic size and amounts of irriga-
tion solution (Table 1). HR and MAP were comparable
between both groups at different times of measurement intra-
operatively and in PACU (P> 0.05) but signiﬁcant difference
was noted within the groups after SA when compared with
baseline values (P< 0.05) (Figs. 1 and 2). While maintaining
the ambient temperature in the operating room between 22
and 24 C, the average baseline core body temperature for
group C was 37.00 ± 08 and for group D was 37.01 ± 10
(p> 0.05). At the end of TURP procedure it was
35.29 ± 19 for group C and 35.31 ± 22 for group D
(p> 0.05). At one hour postoperatively while maintaining
the ambient temperature in the PACU between 25 and
26 C, core temperature for group C was 36.27 ± 32 and for
group D was 36.40 ± 33 (p> 0.05). Core temperature was
signiﬁcantly reduced after SA compared with baseline values
within the groups (P< 0.05) (Fig. 3). Based on Crossley and
Mahajan scale the incidence of shivering was signiﬁcantly
reduced in group D compared with group C (p< 0.001) where
6/40 patients (15%) in group D developed shivering (four
patients with grade 1 and two patients with grade 2) while
23/40 patients (57%) in group C developed shivering (ten
patients with grade 1, seven patients with grade 2 and six
patients with grade 3). No patient in both groups developed
grade 4 shivering (Table 2). No signiﬁcant difference as regards
preoperative and postoperative values of hemoglobin and
serum sodium (P> 0.05) was obtained (Table 3). The fre-
quency of bradycardia (6 patients vs. one patient), hypotensionTable 1 Patient characteristics, prostatic size (g), amount of irriga
among studied groups.
Variables Group C (n= 40)
Age (years) 59.40 ± 7.21
BMI (kg/m2) 25.97 ± 1.81
Prostatic size (g) 54.58 ± 6.15
Anesthesia time (min) 106.83 ± 5.58
Surgery time (min) 79.88 ± 8.20
Irrigation solution (liter/patient) 52.18 ± 3.82
Group C: Control group, group D: Dexmedetomidine group, n: number
Data are presented as mean ± SD.(8 patients vs. 2 patients), number of patients treated with
meperidine (6 patients vs. no patient) and ephedrine (8 patients
vs. 2 patients) were signiﬁcantly higher in group D compared
with group C (P= 0.048, P= 0.043, P= 0.011, P= 0.043)
respectively (Table 4). There was no signiﬁcant difference in
the incidence of nausea, vomiting and TUR syndrome
in patients in both groups (p> 0.05) (Table 4). No patient
in both groups had respiratory depression or needed GA due
to failed SA (see Fig. 4).
5. Discussion
The thermoregulatory mechanism in human body is a complex
one that normally keeps the temperature within a tight range
(36.5–37.5 C) known as ‘‘inter-threshold range’’. If the core
temperature decreases below that range, the body responds
by vasoconstriction and shivering which increases heat produc-
tion two to ﬁve folds [16]. Thus, shivering is a protective mech-
anism to preserve body heat but no deﬁnite linear relationship
exists between body temperature and occurrence of shivering
[17]. SA induces inhibition of vasoconstriction below the level
of anesthesia through sympathetic and somatic blockade with
subsequent vasodilatation and increases cutaneous blood ﬂow
that results in increasing heat loss via the skin [18]. In contrast
to these changes, vasoconstriction and shivering are restricted
to the upper body during SA [8]. The exact mechanism of shiv-
ering during SA has not been fully established. The possible
mechanisms include cessation of central thermoregulation,
internal redistribution of body heat and heat loss to the envi-
ronment [13]. Shivering which is a rhythmic contraction of a
group of muscle has anesthetic and surgical drawbacks. It
increases O2 consumption and CO2 production with subse-
quent increase in basal metabolic rate. Shivering interferes
with patient’s monitoring and it may be a problem in old
patients who is undergoing TURP as most of them have one
or more associated comorbidities with limited cardiac and
respiratory reserve. It may also lead to urethral injury, induce
more bleeding and be associated with uncomfortable surgery
[19]. Shivering is mostly a response to hypothermia [20]. How-
ever, it may be seen in normothermic patients under SA [2].
Risk factors for hypothermia in spinal anesthesia are aging,
level of sensory block, and temperatures of the local anesthetic,
operating room and intravenous solutions [8,13]. In the current
study, the temperature of the operating room was maintained
at 22–24 C. Intravenous and irrigation solutions were also
maintained at 37 C during surgery. Pharmacological
therapies, such as opioid peptides, tramadol, physostigmine,nt solution (liter/patient) anesthesia and surgery time (minutes)
Group D (n= 40) P-value
60.65 ± 7.97 0.464
25.42 ± 1.44 0.136
55.65 ± 6.08 0.434
108.40 ± 9.99 0.388
78.87 ± 3.55 0.482
50.58 ± 4.89 0.107
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Figure 1 Intraoperative and postoperative heart rate changes (beats/min) among groups. Data are presented as mean ± SD. Group C:
Control group, group D: Dexmedetomidine group.
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Figure 2 Intraoperative and postoperative mean arterial blood pressure changes (mmHg) among groups. Data are presented as
mean ± SD. Group C: Control group, group D: Dexmedetomidine group.
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Figure 3 Perioperative core body temperature changes (C) among groups. Data are presented as mean ± SD. Group C: Control group,
group D: Dexmedetomidine group.
184 H.E.S. Moawad, M.M. Elawdyclonidine, ketamine, and magnesium sulfate, have been used to
prevent shivering [7,13]. Meperidine is among opioids, which is
extensively studied due to its anti-shivering effect. Disadvan-
tages of meperidine include nausea, vomiting and respiratory
depression. Fentanyl and morphine could control shiveringbut it should be given in large doses to be effective with
increase of the incidence of side effects [21]. Tramadol may
cause nausea, vomiting and respiratory depression during
and after SA. The hypertensive and tachycardic effects of ket-
amine may limit its use [8]. Magnesium sulfate also has been
Table 2 Preoperative and postoperative values of hemoglobin (Hg) g/L and serum sodium (Na) mmol/L among studied groups.
Variables Group C (n= 40) Group D (n= 40) P-value
Preoperative Hg (g/L) 128.30 ± 12.10 125.80 ± 12.40 0.364
Postoperative Hg (g/L) 110.90 ± 10.20 109.50 ± 09.80 0.540
Preoperative sodium (mmol/L) 137.93 ± 2.96 138.18 ± 3.05 0.711
Postoperative sodium (mmol/L) 128.03 ± 3.77 128.48 ± 3.34 0.574
Group C: Control group, group D: Dexmedetomidine group, n: number.
Data are presented as mean ± SD.
Table 3 Intraoperative and postoperative number and per-
centage of patients with different shivering scores among
studied groups.
Shivering score Group C (n= 40) Group D (n= 40) P-value
0 17 (42.5%) 34 (85%)* <0.001
1 10 (25%) 4 (10%) 0.077
2 7 (17.5%) 2 (5%) 0.077
3 6 (15%) 0 (0%)* 0.011
4 0 (0%) 0 (0%) –
Group C: Control group, group D: Dexmedetomidine group, n:
number.
Data are presented as number and percentage.
* Signiﬁcant difference compared with group C.
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action is uncertain and also it has side effects such as nausea,
vomiting, feeling warm, ﬂushing; it may induce respiratory
depression [22]. Dexmedetomidine is highly selective a 2 adren-
ergic receptors agonist. It is approved to have sedative, analge-
sic, perioperative sympatholytic, anesthetic-sparing, and
hemodynamic-stabilizing properties [10]. It is highly lipophilic,
the fact that may facilitate its rapid absorption into the cere-
brospinal ﬂuid and binding to the spinal cord a 2 adrenocep-
tors [23]. The quality of the spinal anesthesia has been
reported to be improved by the addition of dexmedetomidine
[10] with less hypotensive effect and an added sedative effect
without respiratory depression [13]. Activation of a 2 adrener-
gic receptors in the brain and spinal cord by dexmedetomidine
decreases sympathetic tone and attenuates the neuroendocrine
and hemodynamic responses to anesthesia and surgery. Thus,
dexmedetomidine can mediate both the beneﬁcial and
unwanted effects of shivering provoked by hypothermia, such
as increased catecholamine concentrations, oxygen consump-
tion, blood pressure, and heart rates [13]. In the current study,
the patients in dexmedetomidine group shivered less (6/40)Table 4 Incidence of adverse effects and number of patients receiv
Variables Group C (n= 40
Patients with bradycardia 1 (2.5%)
Patients with hypotension 2 (5%)
Patients with nausea and vomiting 2 (5%)
Patients with TUR syndrome 2 (5%)
Patients received meperidine 6 (15%)
Patients received ephedrine 2 (5%)
Group C: Control group, group D: Dexmedetomidine group, n: number
Data are presented as number (percentage).
* Signiﬁcant difference (p< 0.05) compared with group C.(15%) with lower grades of shivering (two patients grade 2
and four patients grade 1) and no patients received meperidine
to stop shivering compared with higher grades (six patients
grade 3, seven patients grade 2 and ten patients grade 1),
higher incidence (23/40) (57%) of shivering and 6 patients
received meperidine to stop shivering in control group. In a
prospective controlled study upon 60 patients that evaluated
the effect of dexmedetomidine on shivering during SA, Usta
et al. reported a similar results, 3/30 (20%) in dexmedetomi-
dine group and 17/30 (56%) in the control group developed
shivering (p= 0.001) [13].
In agreement with our results, Coskuner et al. [24] reported
signiﬁcant decrease in shivered patients in dexmedetomidine
group, with a signiﬁcant increase in patients experiencing
bradycardia that was safely treated with atropine. In a pla-
cebo-controlled study upon 120 patients that evaluated the
efﬁcacy of dexmedetomidine compared with meperidine and
placebo in preventing postanesthesia shivering after elective
abdominal or orthopedic surgery, Bicer and colleagues [25]
reported that, 22 patients (55%) in the placebo group, four
patients (10%) in the meperidine group and six patients
(15%) in the group D developed shivering. They concluded
that intraoperative dexmedetomidine 1 lg/kg administered
intravenously reduces postanesthesia shivering as does meper-
idine 0.5 mg/kg in patients after major surgery. These results
support the results of the current study. Also, in a prospective
controlled study upon 90 patients that evaluated the effect of
dexmedetomidine on postoperative shivering in patients
undergoing elective abdominal hysterectomy, Elvan and col-
leagues [26] reported a similar results, 7/45 (15%) in dexmede-
tomidine group and 21/45 (46%) in saline group developed
shivering (P= 0.001). The incidence of bradycardia that safely
treated with atropine was higher in dexmedetomidine group.
In agreement with our results, a randomized controlled trial
upon 62 patients that evaluated the role of dexmedetomidine
5 lg added to heavy bupivacaine 0.5% intrathecally for lower
abdominal surgeries, reported lower incidence of shivering ined meperidine and ephedrine among studied groups.
) Group D (n= 40) P-value
6 (15%)* 0.048
8 (20%)* 0.043
2 (5%) 1.0
1 (2.5%) 0.556
0 (0%)* 0.011
8 (20%)* 0.043
.
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186 H.E.S. Moawad, M.M. Elawdydexmedetomidine group (2/31) compared with (12/31) in con-
trol group. Bradycardia was observed more (8/31) among
patients in dexmedetomidine group while no patient in control
group experienced bradycardia [27]. In the current study, HR
and MAP started to decrease after SA in both groups at
different times of measurement. This decrease however was
not statistically signiﬁcant between both groups but was lower
in group D. The bradycardia and hypotension observed in dex-
medetomidine group were tolerable and safely treated without
rebound effect in accordance with other reports [13,28]. The
incidence of nausea, vomiting and TUR syndrome was
insigniﬁcant between both groups in accordance with other
reports [8,13,17]. In this study, no patients in both groups
had respiratory depression or needed GA due to failed SA.
A limitation of this study, the time to shivering was not
estimated and we did not assess different doses of dexmede-
tomidine; further studies are needed to evaluate the effects of
dexmedetomidine with various doses.
6. Conclusion
Our results suggest that the use of 10 lg intrathecal dexmede-
tomidine in patients undergoing TURP has a noticeable
control of shivering even in occurrence of tolerable side effects.Financial support
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